David Heal has been invited to speak at this meeting which has been organised by CCALC, the Cross-Company Abuse Liability Council. It will be held on 27-28th September 2023 at the Hilton Washington DC/Rockville Hotel and Executive Meeting Center.
CCALC Conferences bring together representatives from the pharmaceutical industry, service providers, academia and the FDA to reach a consensus view on addressing new challenges in evaluation of the abuse potential and dependence of CNS-active drugs.
The meeting this year includes a session on the preclinical and clinical assessment of the abuse liability of novel psychedelic drug-candidates.
David will be speaking and a panelist for the session ‘Topic #4: Methodological Considerations for the Abuse Potential Evaluation of Psychedelics’ to be held during the afternoon of 27th September.
The title of his presentation is : ‘Translationally valid experimental designs to evaluate the abuse potential of psychedelic drugs.’
David will be describing how we need to modify and refine non-clinical testing procedures to determine the risks to patients and society posed by the next generation of psychedelics.
His slides will be available after the meeting on the Cross-Company Abuse Liability Council website.
If you are developing novel psychedelics for therapeutic use and would like more information about our experience and expertise in this area please get in touch.